706
Participants
Start Date
March 1, 2019
Primary Completion Date
March 2, 2020
Study Completion Date
March 25, 2021
NNC0174-0833
Participants will get one dose of NNC0174-0833 once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
Placebo (NNC0174-0833)
Participants will get one dose of Placebo (NNC0174-0833) once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
Liraglutide 3.0 mg
Participants will get one dose of liraglutide 3.0 mg once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg daily. The participants will continue on 3.0 mg of liraglutide, once daily up to 26 weeks.
Placebo (Liraglutide 3.0 mg)
Participants will get one dose of Placebo (liraglutide 3.0 mg) once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg. The participants will continue on Placebo (liraglutide 3.0 mg), once daily up to 26 weeks.
Dr Wilhase's rooms, Boksburg
Dr R Dulabh, Johannesburg
Hvidovre Hospital Endokrinologisk forsknings afsnit 159, Hvidovre
Dr Vawda's site, Durban
Dr J Reddy, Durban
Aarhus Universitetshospital Diabetes og Hormonsygdomme, Aarhus N
FARMOVS (Pty) LTD, Bloemfontein
Endocrinology, Diabetes and Metabolism Diseases Clinic, Belgrade
Rochester Clinical Research, Inc., Rochester
Turku University Hospital, Turku
Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis., Novi Sad
Washington Center For Weight Management And Research,Inc., Arlington
National Clinical Research Inc., Richmond
PharmQuest, Greensboro
Spartanburg Medical Research, Spartanburg
Spectrum Medical Research, LLC, Gaffney
Medical University of South Carolina, Charleston
St Johns Center For Clinical Research, Ponte Vedra
Jacksonville Center For Clinical Research, Jacksonville
South Broward Research LLC, Pembroke Pines
Nature Coast Clinical Research, Crystal River
StudyCor, Jyväskylä
Family Practice Center of Wadsworth, Inc., Wadsworth
Prestige Clinical Research, Franklin
Cedar-Crosse Research Center, Chicago
Itä-Suomen yliopisto, Kuopio
Lynn Institute of Norman, Norman
Texas Diabetes & Endocinology, Round Rock
Encompass Clinical Research, Spring Valley
Anaheim Clinical Trials, LLC, Anaheim
Centennial Medical Group, Elkridge
Infinity Medical Research, North Dartmouth
Albert J Weisbrot, Mason
Holston Medical Group Pc, Bristol
University of Calgary, Calgary
C-endo Diabetes & Endocrinology Clinic, Calgary
C-endo Diabetes & Endocrinology Clinic, Edmonton
The Wharton Medical Clinic Clinical Trials, Hamilton
Hamilton Medical Research Group, Hamilton
Obesity Research Unit, University of Helsinki
Clinical Research Centre, St. Vincent's University Hospital,, Dublin
Tokyo-Eki Center-building Clinic, Tokyo
Tokyo Center Clinic, Tokyo
ToCROM Clinic, Tokyo
Gabinet Leczenia Otylosci i Chorob Dietozaleznych, Bialystok
Centrum Medyczne Salvia, Katowice
Centrum Zdrowia Metabolicznego, Poznan
The Health Centre, Bradford-on-Avon
Southmead Hospital, Bristol
WISDEM Centre, Coventry
University Hospital Aintree, Liverpool
Guys Hospital, London
UCL - Obesity, London
Clifton Medical Centre, Rotherham
Lead Sponsor
Novo Nordisk A/S
INDUSTRY